Cargando…
Quantification of cancer driver mutations in human breast and lung DNA using targeted, error‐corrected CarcSeq
There is a need for scientifically‐sound, practical approaches to improve carcinogenicity testing. Advances in DNA sequencing technology and knowledge of events underlying cancer development have created an opportunity for progress in this area. The long‐term goal of this work is to develop variatio...
Autores principales: | Harris, Kelly L., Walia, Vijay, Gong, Binsheng, McKim, Karen L., Myers, Meagan B., Xu, Joshua, Parsons, Barbara L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756507/ https://www.ncbi.nlm.nih.gov/pubmed/32940377 http://dx.doi.org/10.1002/em.22409 |
Ejemplares similares
-
Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk
por: Harris, Kelly L., et al.
Publicado: (2019) -
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas()()
por: Myers, Meagan B., et al.
Publicado: (2016) -
Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution
por: Cameron, Laird B, et al.
Publicado: (2017) -
Variation in organ‐specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas
por: Parsons, Barbara L., et al.
Publicado: (2017) -
Korean Cardiac Arrest Research Consortium (KoCARC): rationale, development, and implementation
por: Kim, Joo Yeong, et al.
Publicado: (2018)